TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16409457
Drug: High-dose antithrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose antithrombin (AT)
Study: 8493292
Drug: Hormonal levels
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal levels (thyroid stimulating hormone, free triiodothyronine, prolactin, cortisol)
Study: 2942050
Drug: Intravenous ketanserin
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketanserin 10 mg
Study: 2942050
Drug: Intravenous ketanserin
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketanserin 20 mg
Study: 2942050
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection of saline
Study: 27261936
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine (3 mg/kg body weight)
Study: 25029008
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid (DHA) 2 g/day for 28 days
Study: 25029008
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) 2 g/day for 28 days
Study: 22659999
Drug: Vitamin B‐12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B‐12 (500 µg/day) for 12 weeks
Study: 16171665
Drug: Tramadol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1.5 mg/kg IV followed by continuous infusion of 0.5 mg/kg per hour until the end of surgery (group I)
Study: 12854475
Drug: 2 mg.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg.kg-1 propofol (group P2)
Study: 12854475
Drug: 1 mg.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg.kg-1 propofol (group P1)
Study: 12854475
Drug: Intralipid 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid 0.2 ml.kg-1 (group C)
Study: 9884384
Drug: Isoproterenol (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol (before NG‐monomethyl‐L‐arginine)
Study: 9884384
Drug: Isoproterenol (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol (after NG‐monomethyl‐L‐arginine)
Study: 1651071
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 13‐cis‐retinoic acid
Study: 1651071
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of all‐trans‐retinoic acid
Study: 1651071
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of arotinoid methyl sulphone
Study: 1651071
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of arotinoid ethyl sulphone
Study: 30716769
Drug: Placebo creams
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo creams
Study: 6352603
Drug: Azlocillin (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azlocillin (group I) at mean dosage of 252 mg/kg/day for a mean duration of 13.2 days
Study: 6352603
Drug: Carbenicillin (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenicillin (group II) at mean dosage of 505 mg/kg/day for a median duration of 12.6 days
Study: 26575606
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment initiation in overt diabetes
Study: 12377958
Drug: EPI alone
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI alone (60 mg/m(2) on days 1 and 2 every 21 days)
Study: 12377958
Drug: EPI and
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI and CDDP (30 mg/m(2) on days 1 and 2 every 21 days)
Study: 12377958
Drug: EPI and
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI and LND (450 mg orally daily, given continuously)
Study: 7863045
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (AB) 50-100 mg/day
Study: 821075
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered thyrotropin-releasing hormone (TRH) at a dosage of 200 to 300 mg daily
Study: 31610635
Drug: Delivery mode,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivery mode, feeding method and antibiotic exposure
Study: 28599630
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (1.8 g daily, containing 1.08 g of EPA and 0.72 g of DHA)
Study: 21709652
Drug: i.v. midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. midazolam 1 mg
Study: 21709652
Drug: i.v. midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. midazolam 3 mg
Study: 14711553
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg, p.o. b.i.d.)
Study: 11355560
Drug: Iron‐folate supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron‐folate supplements (36 mg iron and 5 mg folate daily)
Study: 11355560
Drug: Control (neither
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (neither albendazole nor iron‐folate supplements)
Study: 9146577
Drug: Vaginal mucosal
Normalized name: Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal mucosal immunization (vaccine treated)
Study: 29342272
Drug: Qualitative interviews
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative interviews regarding decision-making about food and drink, dietary supplements, medications, alcohol, and recreational drugs.
Study: 28126600
Drug: Romifidine 60
Normalized name: romifidine
DrugBank: Romifidine (DB11543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romifidine 60 μg/kg IV (R60)
Study: 28126600
Drug: Romifidine 80
Normalized name: romifidine
DrugBank: Romifidine (DB11543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romifidine 80 μg/kg IV (R80)
Study: 28126600
Drug: Romifidine 100
Normalized name: romifidine
DrugBank: Romifidine (DB11543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romifidine 100 μg/kg IV (R100)
Study: 28126600
Drug: Romifidine 40
Normalized name: romifidine
DrugBank: Romifidine (DB11543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romifidine 40 μg/kg IV (R40)
Study: 28126600
Drug: Acepromazine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acepromazine 0.1 mg/kg IV (ACE)
Study: 28126600
Drug: Saline (0.9%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.9%, 5 mL IV)
Study: 23176568
Drug: Nanoparticle paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nanoparticle paclitaxel 300 mg/m² (NP300)
Study: 23176568
Drug: Nanoparticle paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nanoparticle paclitaxel 220 mg/m² (NP220)
Study: 23176568
Drug: Cremophor paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cremophor paclitaxel 175 mg/m² (CP175)
Study: 22000624
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of oxygenation, blood cultures, rapid initiation of antibiotic therapy <4 hours, appropriate selection of antibiotic therapy
Study: 18434883
Drug: Piperacillin/tazobactam 12/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam 12/1.5 g/day after a loading dose of 4/0.5 g
Study: 18434883
Drug: Piperacillin/tazobactam 16/2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam 16/2 g/day after a loading dose of 4/0.5 g
Study: 16256232
Drug: CHART treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHART treatment
Study: 1318678
Drug: Daptomycin 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin 2.0 mg/kg
Study: 1318678
Drug: Daptomycin 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin 3.0 mg/kg
Study: 1318678
Drug: Daptomycin 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin 4.0 mg/kg
Study: 1318678
Drug: Daptomycin 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin 6.0 mg/kg
Study: 1318678
Drug: Daptomycin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin 1.0 mg/kg (14C-labeled)
Study: 1318678
Drug: Daptomycin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin 0.5 to 6.0 mg/kg
Study: 1318678
Drug: Daptomycin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (all doses)
Study: 1318678
Drug: Daptomycin (predicted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (predicted effective doses)
Study: 30741801
Drug: Oxytocin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (30 units in 500 mL of intravenous fluid)
Study: 30741801
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mL of intravenous fluid alone)
Study: 27724859
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (0.15 μg·kg−1·min−1) followed by immobility
Study: 17294149
Drug: Atypical antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotic drugs combined with psychotherapy
Study: 16118079
Drug: 6 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 courses of anthracycline-based chemotherapy (CT group)
Study: 12270028
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg taken 4 hours before expected time of sex for 6 months
Study: 10052020
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg vitamin C capsule daily during weeks 4-5
Study: 10052020
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule daily during weeks 1-3
Study: 2174464
Drug: Infusion regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion regimen of etoposide (VP‐16) and cisplatin (CDDP)
Study: 2174464
Drug: Infusion regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion regimen
Study: 6999637
Drug: Danazol treatment
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol treatment for 6 months
Study: 29522648
Drug: Darifenacin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin 10 mg or 20 mg
Study: 24222312
Drug: High-dose-rate (HDR)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate (HDR) brachytherapy and hypofractionated external beam radiotherapy (EBRT) with long-term androgen deprivation therapy (ADT)
Study: 2178566
Drug: Acetyl-salicylic acid
Normalized name: acetyl salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-salicylic acid (ASA) 1000 mg/day
Study: 89499
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B immunoglobulin (HBIg) 0.5 ml/kg within 48 hours after birth and 0.16 ml/kg every month for 6 months
Study: 30079635
Drug: Terlipressin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin infusion (1 mg bolus over 30 minutes followed by 2 μg/kg/h continuous infusion)
Study: 23507223
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (2 capsules and 4 cups water per day)
Study: 19470058
Drug: Strip patch
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Strip patch test (SPT)
Study: 19470058
Drug: Conventional patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional patch test (PT)
Study: 17052563
Drug: i.v. ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketamine 1 mg/kg
Study: 17052563
Drug: i.m. ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. ketamine 4 mg/kg
Study: 8522684
Drug: Intracoronary isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary isosorbide dinitrate (2 mg)
Study: 6303624
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of thallium score, appearance of Q waves, and ejection fraction
Study: 30215545
Drug: Leniolisib (CDZ173),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leniolisib (CDZ173), single oral dose of 400 mg
Study: 26823180
Drug: Intensive journal
Normalized name: Journavx
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive journal club treatment arm
Study: 22166903
Drug: Salbutamol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (15 μg/kg ideal bodyweight per h) for up to 7 days
Study: 20702657
Drug: Recombinant EBA‐175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant EBA‐175 vaccine with aluminum phosphate adjuvant (5, 20, 80, or 160 μg) administered at 0, 1, and 6 months
Study: 20702657
Drug: Recombinant EBA‐175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant EBA‐175 vaccine with aluminum phosphate adjuvant (3 doses at any concentration)
Study: 17717960
Drug: Ketamine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0, 1, or 10 mmol/L)
Study: 17717960
Drug: Glutamate (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamate (0.2 mL, 1 mol/L)
Study: 8580384
Drug: IL‐1 alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐1 alpha (0.03 g/kg as a 30 minute infusion daily for 5 days)
Study: 8580384
Drug: IL‐6 (5-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐6 (5-day continuous infusion)
Study: 31567579
Drug: Ketorolac with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac with opioid medication
Study: 28513346
Drug: Psychoeducation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducation and Problem Solving (PEPS) therapy
Study: 19731968
Drug: Haloperidol 7-10
Normalized name: haloperidol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 7-10 mg/day
Study: 17324745
Drug: hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide (25 mg)
Study: 7979935
Drug: 20% benzocaine
Normalized name: BENZOCAINE 200 mg in 1 g DENTAL GEL [Ipana 20% Benzocaine Topical]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% benzocaine spray
Study: 7979935
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (benzocaine and placebo)
Study: 7979935
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic (benzocaine)
Study: 2658886
Drug: Automated control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated control of sodium nitroprusside administration
Study: 2658886
Drug: Manual control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual control of sodium nitroprusside administration
Study: 31819387
Drug: Resveratrol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol + Curcumin (500 mg each daily)
Study: 29088038
Drug: PAI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAI with liposomal bupivacaine, ketorolac, and epinephrine (PAI-L)
Study: 18095965
Drug: Propofol-ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-ketamine (1 mg.kg(‐1) ketamine + 1.2 mg.kg(‐1) propofol)
Study: 18095965
Drug: Propofol-fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-fentanyl (1 microg.kg(‐1) fentanyl + 1.2 mg.kg(‐1) propofol)
Study: 8616947
Drug: L-arginine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (30 g, intravenous infusion, 60 minutes)
Study: 8616947
Drug: PGE1 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE1 (40 microgram, intravenous infusion, 60 minutes)
Study: 8616947
Drug: Placebo (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (150 mL 0.9% saline, intravenous infusion, 60 minutes)
Study: 3907738
Drug: sobrerol 400
Normalized name: sobrerol
DrugBank: Sobrerol (DB13315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sobrerol 400 mg day-1 for 14 days
Study: 11246060
Drug: Negative or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative or neutral trial (MACH‐1 trial of mibefradil, REACH trial of bosentan, CASCO trial of calcium sensitizer, ecadotril trial of neutral endopeptidase inhibitor)
Study: 7978587
Drug: Rectal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal midazolam (0.45 mg/kg)
Study: 4156290
Drug: Potassium clorazepate
Normalized name: potassium clorazepate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium clorazepate (15 mg. at night)
Study: 4156290
Drug: Lorazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1 mg. t.d.s.)
Study: 30785198
Drug: GEMOX (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEMOX (gemcitabine 1000 mg/m2 on days 1 and 8, and oxaliplatin 100 mg/m2 on day 1)
Study: 30785198
Drug: XELOX (capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX (capecitabine 1000 mg/m2, twice daily, on days 1‐14 and oxaliplatin 130 mg/m2 on day 1)
Study: 29768118
Drug: Chemotherapy (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 or carboplatin)
Study: 16938161
Drug: Group G
Normalized name: Prostaglandin group G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group G (General anaesthesia with propofol 2 mg kg‐1 and fentanyl 100 microg)
Study: 16938161
Drug: Group S
Normalized name: Blood group substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S (Spinal anaesthesia with propofol infusion at 2 mg kg‐1 h‐1 after a 0.2 mg kg‐1 bolus dose and fentanyl 100 microg)
Study: 16938161
Drug: Group T
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group T (TIVA with propofol 2 mg kg‐1 and fentanyl 100 microg)
Study: 30997542
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel dressings
Study: 28247679
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus Miramistin
Study: 24684985
Drug: SD‐Ag and
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD‐Ag and mupirocin (combination)
Study: 24684985
Drug: SD‐Ag, mupirocin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD‐Ag, mupirocin, and clotrimazole (combination)
Study: 17533081
Drug: Multidisciplinary literature-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary literature-based approach to treatment
Study: 16322283
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy with Premarin
Study: 12081832
Drug: Folate supplement
Normalized name: Folate supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folate supplement (400 microg/d)
Study: 12081832
Drug: Exclusion diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exclusion diet (placebo daily)
Study: 9459155
Drug: Tamoxifen alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen alone (40 mg per day)
Study: 9459155
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (40 mg of tamoxifen + 75 microg of CV 205-502 + 3 x 0.2 mg of octreotide)
Study: 7871564
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g of eicosapentanoic acid (EPA)
Study: 7871564
Drug: 18 g
Normalized name: flotufolastat F 18 gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g of eicosapentanoic acid (EPA)
Study: 7871564
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g of corn oil (placebo)
Study: 7871564
Drug: 18 g
Normalized name: flotufolastat F 18 gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g of corn oil (placebo)
Study: 7871564
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose fish oil (EPA)
Study: 7871564
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose fish oil (EPA)
Study: 2371432
Drug: Routine follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine follow-up at 3 monthly intervals (follow-up group)
Study: 7362785
Drug: No anti-hypertensive
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-hypertensive treatment (Control)
Study: 23984100
Drug: 7.5% povidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% povidone iodine otic drops
Study: 14988571
Drug: Anticoagulation (adjusted-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation (adjusted-dose warfarin)
Study: 8890138
Drug: Amoxicillin (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (first choice antibiotic for AOM)
Study: 19487582
Drug: All 4
Normalized name: Flex-All 454
Approvals — FDA: no, EMA: no, PMDA: no
Description: All 4 classes of drug
Study: 9380803
Drug: Chlorpromazine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (2.5 mg/l of dialysis solution)
Study: 9380803
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (5 mg/l of dialysis solution)
Study: 9380803
Drug: Isoprenaline hydrochloride
Normalized name: Isoprenaline hydrochloride
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline hydrochloride (0.5 mg/l of dialysis solution)
Study: 9380803
Drug: 1.5 g%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g% glucose dialysis solution
Study: 7871062
Drug: Melatonin 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 80 mg
Study: 30255400
Drug: Amiodarone (AMIO)
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiodarone (AMIO) monotherapy (300 mg in 30 min + 1125 mg in 36 h iv)
Study: 30255400
Drug: Amiodarone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone plus Ranolazine (AMIO + RAN) combination (500 mg po + 375 mg after 6 h and 375 mg twice daily thereafter)
Study: 27496105
Drug: Levosimendan infusion
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan infusion (0.1 μg/kg/min for 24 hours)
Study: 24650009
Drug: Sotatercept (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotatercept (0.1, 0.3, or 0.5 mg/kg)